Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 186 700 KRW 0.54% Market Closed
Market Cap: 43.1T KRW

Celltrion Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Celltrion Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Inc
KRX:068270
Operating Income
₩889.7B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
15%
SK Bioscience Co Ltd
KRX:302440
Operating Income
-₩138.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Operating Income
-₩36.3B
CAGR 3-Years
-50%
CAGR 5-Years
8%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Operating Income
₩169.2B
CAGR 3-Years
43%
CAGR 5-Years
50%
CAGR 10-Years
28%
Alteogen Inc
KOSDAQ:196170
Operating Income
₩75.5B
CAGR 3-Years
N/A
CAGR 5-Years
59%
CAGR 10-Years
N/A
A
ABL Bio Inc
KOSDAQ:298380
Operating Income
-₩22.1B
CAGR 3-Years
23%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Inc
Glance View

Celltrion Inc. stands as a significant player in the global biopharmaceutical industry, rooted in the heart of South Korea's bustling innovation scene. Founded in 2002 by Seo Jung-Jin, the company initially carved its niche in the development of biosimilars, which are near-identical versions of original biological drugs whose patents have expired. With rapid advancements in biotechnology, Celltrion has well-positioned itself to tap into the expanding market for affordable and accessible biologic treatments. At the core of its operation is its cutting-edge production facilities equipped with high-tech fermentation and purification processes necessary for manufacturing these complex medicines. This foundational expertise has allowed Celltrion to pioneer some of the world's first monoclonal antibody biosimilars, including those for autoimmune diseases and oncological conditions, thereby cementing its reputation as a forerunner in global biosimilar development. The company’s revenue model is intricately tied to its production capabilities and strategic partnerships. By leveraging its advanced manufacturing infrastructure, Celltrion not only produces its own line of biosimilars but also collaborates with global pharmaceutical companies to license and distribute its products worldwide. Such partnerships have enabled Celltrion to penetrate markets across Europe, the Americas, and Asia, with its biosimilars gaining regulatory approval in many regions. Furthermore, Celltrion’s business is not limited to biosimilars; it is actively investing in novel biologics and innovative delivery systems. This diversification strategy underscores its commitment to sustainable growth and reducing dependence on any single product line, ultimately fostering a robust pipeline that promises to meet the healthcare industry's evolving demands.

Celltrion Inc Intrinsic Value
HIDDEN
Show

See Also

What is Celltrion Inc's Operating Income?
Operating Income
889.7B KRW

Based on the financial report for Sep 30, 2025, Celltrion Inc's Operating Income amounts to 889.7B KRW.

What is Celltrion Inc's Operating Income growth rate?
Operating Income CAGR 10Y
15%

Over the last year, the Operating Income growth was 183%. The average annual Operating Income growth rates for Celltrion Inc have been 6% over the past three years , 6% over the past five years , and 15% over the past ten years .

Back to Top